Skip to content 
Search

Latest Stories

Bryan Johnson may shut down anti-ageing startup to focus on religion

Tech entrepreneur Bryan Johnson says he may exit anti-ageing venture

Bryan Johnson

He now believes that commercial interests may be at odds with his philosophical mission

Getty Images

Highlights

  • Bryan Johnson, 47, is contemplating shutting down or selling his anti-ageing startup, Blueprint.
  • The biotech entrepreneur recently launched a religion called "Don’t Die."
  • He says commercial activity is undermining his philosophical credibility.
  • Blueprint has faced financial pressures but Johnson denies any crisis.

Biotech entrepreneur and longevity enthusiast Bryan Johnson has revealed he is considering shutting down or selling his anti-ageing company, Blueprint. Speaking to Wired, the 47-year-old said his priorities have shifted towards developing his newly founded religion, "Don’t Die", which he believes better aligns with his philosophical ambitions.

“I am so close to either shutting it down or selling it,” Johnson said in the interview published Monday. “I don’t need the money, and it’s a pain-in-the-ass company.”


From business to belief

Johnson is widely known for Project Blueprint, his intense and expensive self-experimentation regimen aimed at reversing ageing. Launched in 2021, the programme reportedly costs him around $2 million annually and has included controversial practices such as blood transfusions from his son, which he later discontinued due to lack of observable benefits.

Blueprint, his startup, sells wellness products ranging from a £42 mushroom-based coffee alternative called “Super Shrooms” to a £44 “longevity mix” drink.

In March, Johnson publicly declared the founding of his own religion, “Don’t Die”, which evolved from the tagline of his wellness brand and Netflix documentary. “It seemed obvious that they’d say Don’t Die is how humanity saved itself and merged with AI,” he wrote on X.

However, he now believes that commercial interests may be at odds with his philosophical mission. “People see the business and give me less credibility on the philosophy side. I will not make that trade-off,” he told Wired.

Financial pressures and public perception

Earlier this year, The New York Times reported that Blueprint was missing its monthly break-even target by over £780,000 ($1 million), citing internal documents and former employees. Johnson responded to some of the allegations, but notably avoided directly addressing the financial data.

To Wired, he maintained that the company is not in a financial crisis. “We are break-even, and I’ve said that publicly many times. We’ve had profitable months, we’ve had loss months,” he said.

Blueprint originally emerged from requests by friends who were curious about the supplements Johnson was taking. “I was trying to do people a solid,” he said. Yet, the enterprise has grown into something that, he now feels, undermines the authenticity of his philosophical pursuits.

“I don’t want it,” he concluded.

More For You

HPV vaccine 16 to 25

Many of those targeted missed their vaccine during school years

iStock

NHS steps up HPV vaccine rollout for young people aged 16–25

Highlights

  • NHS encourages unvaccinated people aged 16–25 to get the HPV vaccine
  • Over 418,000 school leavers in past three years missed vaccination
  • HPV vaccine protects against cervical and other related cancers
  • NHS aiming for 90% uptake among girls by 2040
  • Letters, emails, texts and NHS App alerts being used for reminders

NHS campaign targets unvaccinated young adults

The NHS is urging hundreds of thousands of young people aged 16 to 25 to come forward for the HPV vaccine, which protects against cervical and other types of cancer.

Many of those targeted missed their vaccine during school years. According to NHS England, over 418,000 children left school without receiving the HPV jab in the past three years.

Keep ReadingShow less
slimming jab Morrisons

The move has sparked criticism on social media

iStock

Morrisons launches £129-a-month weight loss injection service

Highlights

  • Morrisons Clinic introduces subscription service for tirzepatide injections
  • The treatment may aid weight loss of up to 20% over one year
  • Monthly subscription will increase from £129 to £159 after introductory period
  • Service includes medical assessment and regular check-ins
  • Criticism emerges over the supermarket’s continued sale of unhealthy food


Morrisons has launched an online subscription service offering weight loss injections, prompting mixed reactions from the public. The supermarket’s online health platform, Morrisons Clinic, now offers tirzepatide — also known by the brand name Mounjaro — for weight management.

Tirzepatide is primarily prescribed to treat type 2 diabetes, but has also been approved for weight loss. According to Morrisons Clinic, users may lose up to 20 per cent of their body weight over the course of a year.

Keep ReadingShow less
RSV vaccine premature babies

NHS England says premature babies are three times more likely to be hospitalised due to RSV

iStock

NHS to immunise premature babies against deadly winter virus RSV

Highlights

  • NHS to offer nirsevimab injection to 9,000 premature and high-risk babies from late September
  • Aims to protect against respiratory syncytial virus (RSV), which can cause severe illness in infants
  • Premature babies are 10 times more likely to need intensive care for RSV
  • Nirsevimab offers immediate protection and lasts for six months
  • Neo-natal units across the UK will deliver the jab

Thousands of premature and high-risk babies in the UK will soon be offered a new immunisation to protect against RSV (respiratory syncytial virus), a common winter virus that can cause serious lung infections and hospitalisation. The NHS will begin delivering the nirsevimab injection from late September, aiming to shield vulnerable infants before the colder months set in.

Premature infants at higher risk from RSV

RSV typically causes coughs and colds, but in some children — particularly those born prematurely or with underlying health conditions — it can lead to bronchiolitis, pneumonia, and breathing difficulties. NHS England says premature babies are three times more likely to be hospitalised due to RSV and ten times more likely to require intensive care compared to full-term infants.

Keep ReadingShow less
Donald Trump health 2025

The diagnosis has prompted a wave of public attention

Getty Images

What is chronic venous insufficiency, the condition Donald Trump is diagnosed with?

Highlights

  • President Donald Trump has been diagnosed with chronic venous insufficiency (CVI), a vascular condition affecting blood flow in the legs
  • CVI occurs when leg veins struggle to return blood to the heart, often leading to swelling and discomfort
  • The condition was confirmed following visible leg swelling and bruising
  • Though not life-threatening, CVI can worsen without treatment
  • Trump’s case has sparked public interest in the risks and management of the condition

Trump diagnosed with common but chronic vein condition

President Donald Trump has been diagnosed with chronic venous insufficiency, a condition that affects the proper circulation of blood in the legs. The announcement followed public speculation after Trump was seen with visible swelling in his lower legs and bruising on his hand during recent public appearances.

According to a statement from White House medical staff, tests ruled out more serious cardiovascular conditions. Trump, 79, remains under regular observation, with the condition described as benign and manageable.

Keep ReadingShow less
Babies born free of mitochondrial disease

8 babies have been born in the UK using genetic material from 3 people

iStock

Babies born free of mitochondrial disease using DNA from 3 people

Highlights

  • Eight babies were born in the UK using DNA from three individuals to prevent mitochondrial disease
  • The technique combines egg and sperm from parents with mitochondria from a donor egg
  • Legal in the UK since 2015; results show children are meeting expected milestones
  • One in 5,000 babies are born with mitochondrial disease; no known cure exists
  • Newcastle scientists pioneered the technique, now used under NHS specialist service

UK births mark milestone in preventing inherited mitochondrial disease

Eight babies have been born in the UK using genetic material from three people in a pioneering effort to prevent incurable mitochondrial disease, doctors have confirmed. The technique, developed by researchers in Newcastle, represents a significant breakthrough in reproductive medicine and genetic science.

These births are the first proven cases in the UK of healthy children being born free of devastating mitochondrial disorders thanks to this technique, which has been legal in the country since 2015.

Keep ReadingShow less